Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-08-01
2006-08-01
Aulakh, Charanjit S. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S062000, C544S055000, C544S096000, C544S333000, C514S226800, C514S228800, C514S256000
Reexamination Certificate
active
07084151
ABSTRACT:
The present invention is directed to compounds, pharmaceutical compositions, and methods for modulating processes mediated by Progesterone Receptor. Also provided are methods of making such compounds and pharmaceutical compositions.
REFERENCES:
patent: 5506102 (1996-04-01), McDonnell et al.
patent: 5688808 (1997-11-01), Jones et al.
patent: 5688810 (1997-11-01), Jones et al.
patent: 5693646 (1997-12-01), Jones et al.
patent: 5693647 (1997-12-01), Jones et al.
patent: 5696127 (1997-12-01), Jones et al.
patent: 5696130 (1997-12-01), Jones et al.
patent: 5696133 (1997-12-01), Jones et al.
patent: 5808139 (1998-09-01), Pathirana et al.
patent: 5994544 (1999-11-01), Jones et al.
patent: 6001846 (1999-12-01), Bender et al.
patent: 6093821 (2000-07-01), Jones et al.
patent: 6093825 (2000-07-01), Bender et al.
patent: 6093826 (2000-07-01), Edwards et al.
patent: 6121450 (2000-09-01), Jones et al.
patent: 6172241 (2001-01-01), Edwards et al.
patent: 6268497 (2001-07-01), Edwards et al.
patent: 6306851 (2001-10-01), Santilli et al.
patent: 6319912 (2001-11-01), Grubb et al.
patent: 6329416 (2001-12-01), Grubb et al.
patent: 6339098 (2002-01-01), Collins et al.
patent: 6355648 (2002-03-01), Fensome et al.
patent: 6358947 (2002-03-01), Zhi et al.
patent: 6358948 (2002-03-01), Zhang et al.
patent: 6369056 (2002-04-01), Zhang et al.
patent: 6380178 (2002-04-01), Grubb et al.
patent: 6380207 (2002-04-01), Coghlan et al.
patent: 6380235 (2002-04-01), Zhang et al.
patent: 6391907 (2002-05-01), Fensome et al.
patent: 6399593 (2002-06-01), Grubb et al.
patent: 6407101 (2002-06-01), Collins et al.
patent: 6417214 (2002-07-01), Ullrich et al.
patent: 6436929 (2002-08-01), Zhang et al.
patent: 6441019 (2002-08-01), Santilli et al.
patent: 6444668 (2002-09-01), Grubb et al.
patent: 6448405 (2002-09-01), Jones et al.
patent: 6462032 (2002-10-01), Grubb et al.
patent: 6498154 (2002-12-01), Grubb et al.
patent: 6503939 (2003-01-01), Grubb et al.
patent: 6506766 (2003-01-01), Coghlan et al.
patent: 6509334 (2003-01-01), Zhang et al.
patent: 6521657 (2003-02-01), Fensome et al.
patent: 6544970 (2003-04-01), Grubb et al.
patent: 6566358 (2003-05-01), Zhang et al.
patent: 6566372 (2003-05-01), Zhi et al.
patent: 6583145 (2003-06-01), Fensome et al.
patent: 6608068 (2003-08-01), Fensome et al.
patent: 6693103 (2004-02-01), Zhang et al.
patent: 6696459 (2004-02-01), Jones et al.
patent: 6713478 (2004-03-01), Zhang et al.
patent: 6759408 (2004-07-01), Grubb et al.
patent: 6794373 (2004-09-01), Grubb et al.
patent: 6835744 (2004-12-01), Ullrich et al.
patent: 6841568 (2005-01-01), Fensome et al.
patent: 2003/0216388 (2003-11-01), Zhang et al.
patent: 2003/0220388 (2003-11-01), Fensome et al.
patent: 2003/0225109 (2003-12-01), Fensome et al.
patent: 2004/0152717 (2004-08-01), Zhi et al.
patent: 2004/0152718 (2004-08-01), Zhi et al.
patent: 2004/0186101 (2004-09-01), Zhang et al.
patent: WO 96/19458 (1996-06-01), None
patent: WO 99/41256 (1999-08-01), None
patent: 0066103 (2000-11-01), None
patent: 0066163 (2000-11-01), None
patent: 0066164 (2000-11-01), None
patent: 0066165 (2000-11-01), None
patent: 0066166 (2000-11-01), None
patent: 0066167 (2000-11-01), None
patent: 0066168 (2000-11-01), None
patent: 0066225 (2000-11-01), None
patent: 0066554 (2000-11-01), None
patent: 0066555 (2000-11-01), None
patent: 0066556 (2000-11-01), None
patent: 0066560 (2000-11-01), None
patent: 0066564 (2000-11-01), None
patent: 0066570 (2000-11-01), None
patent: 0066571 (2000-11-01), None
patent: 0066574 (2000-11-01), None
patent: 0066581 (2000-11-01), None
patent: 0066590 (2000-11-01), None
patent: 0066591 (2000-11-01), None
patent: 0066592 (2000-11-01), None
patent: 0116108 (2001-03-01), None
patent: WO 02/02565 (2002-01-01), None
patent: WO 99/41257 (2002-04-01), None
patent: 2004033459 (2004-04-01), None
patent: 2004033460 (2004-04-01), None
patent: 2004033461 (2004-04-01), None
Berger, T.S., et al., J. Steroid Biochem. Mol. Bio. 1992, 41, 733-738.
Pathirana, C., et al., Mol. Pharm. 1995, 47, 630-635.
International Search Report for related PCT International Application No. PCT/US03/24416 filed Apr. 8, 2003.
Tegley, C.M. et al., “5-Benzylidene 1,2-Dihydrochromemo[3,4-ƒ]quinolines, A Novel Class of Nonsteroidal Human Progesterone Receptor Agonists” J. Med. Chem. 1998, 41, 4354-4359.
Zhi, L. et al., “Synthesis and Biological Activity of 5-Methylidene 1,2-Dihydrochromeno[3-4-ƒ]quinoline Derivatives as Progesterone Receptor Modulators.”Bioorganic&Medicinal Chemistry Letters13(2003) 2071-2074.
Clemm et al., “Definition of the critical cellular components which distinguish between hormone and antihormone activated progesterone receptor,” Journal of Steroid Biochemistry and Molecular Biology 53(1-6):487-495. (1995).
Crombie et al., “Anti-progesterone effects on maternal recognition and behavior imprinted during first pregnancy in mice,” Journal of Endocrinology 147(2):331-337. (1995).
Edwards et al., “5-Aryl-1,2-dihydro-5H-chromeno[3,4-ƒ]quinolines as potent, orally active, nonsteroidal progesterone receptor agonists: the effect of D-ring substituents,” Journal of Medicinal Chemistry. 41(3):303-310 (1998).
Edwards et al., “Preparation, resolution, and biological evaluation of 5-aryl-1, 2-dihydro-5H-chromeno[3,4-f]quinolines: potent, orally active, nonsteroidal progesterone receptor agonists,” Journal of Medicinal Chemistry 41(15):2779-2785 (1998).
Hamann et al., “Nonsteroidal progesterone receptor antagonists based on a conformationally-restricted subseries of 6-aryl-1,2-dihydro-2,2,4-trimethylquinolines,” Bioorganic & Medicinal Chemistry Letters 8(19):2731-2736 (1998).
Mais et al., “Specific interactions of progestins and anti-progestins with progesterone antibodies, plasma binding proteins and the human recombinant receptor,” Journal of Steroid Biochemistry and Molecular Biology 54(1-2):63-69. (1995).
McDonnell, D.P. and M.E. Goldman, “RU486 exerts antiestrogenic activities through a novel progesterone receptor A form-mediated mechanism,” The Journal of Biological Chemistry 269(16):11945-11949. (1994).
McDonnell et al., “Definition of the cellular mechanisms which distinguish between hormone and antihormone activated steroid receptors,” Seminars in Cancer Biology, 5(5):327-336 (1994).
McDonnell et al., “The human progesterone receptor A-form functions as a transcriptional modulator of mineralocorticoid receptor transcriptional activity,” Journal of Steroid Biochemistry and Molecular Biology 48(5-6):425-432. (1994).
Miner, J.N. and C.M. Tyree, “Drug discovery and the intracellular receptor family,” Vitamins and Hormones. 62:253-280. (2001).
Parandoosh et al., “Progesterone and oestrogen receptors in the decidualized mouse uterus and effects of different types of anti-progesterone treatment,” Journal of Reproduction and Fertility 105(2):215-220. (1995).
Rosen et al., “Intracellular receptors and signal transducers and activators of transcription superfamilies—novel targets for small-molecule drug discovery,” Journal of Medicinal Chemistry 38(25):4855-4874 (1995).
Santiso-Mere, D. and D.P. McDonnell, “Applied nuclear receptor research in the drug discovery process,” Chimica Oggi 12(5-6):29-36. (1994).
Taylor et al., “Activity of progesterone and anti-progestins in a rat mammary primary cell culture system,” Journal of Steroid Biochemistry and Molecular Biology 58(1):117-121 (1996).
Vegeto et al., “Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function,” Molecular Endocrinology. 7(10):1244-1255. (1993).
Wagner et al., “The novel progesterone receptor antagonists RTI 3021-012 and RTI 3021-022 exhibit complex glucocorticoid receptor antagonist activities: Implications for the development of dissociated antiprogestins,” Endocrinology 140(3):1449-1458 (1999).
Wen et al., “The A and B i
Van Oeveren Cornelis Arjan
Zhi Lin
Aulakh Charanjit S.
Fish & Richardson P.C.
Ligand Pharmaceuticals Incorporated
Miskiel Frank J.
Seidman Stephanie
LandOfFree
5-(1',1'-cycloalkyl/alkenyl)methylidene 1,2-dihydro- 5H... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 5-(1',1'-cycloalkyl/alkenyl)methylidene 1,2-dihydro- 5H..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 5-(1',1'-cycloalkyl/alkenyl)methylidene 1,2-dihydro- 5H... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3647915